Enhanced anti-PD-1 therapy in hepatocellular carcinoma by tumor vascular disruption and normalization dependent on combretastatin A4 nanoparticles and DC101
Xin Bao, Na Shen, Yan Lou, Haiyang Yu, Yue Wang, Linlin Liu, Zhaohui Tang, Xuesi Chen
Abstract
These results reveal a novel approach to enhance anti-PD-1 therapy with VDAs + VEGF/VEGFR2 inhibitors in HCC.
Topics & Concepts
Hepatocellular carcinomaMedicineCancer researchOncologyInternal medicineCancer Research and TreatmentsPhagocytosis and Immune RegulationCancer Immunotherapy and Biomarkers